Tech Company Financing Transactions
Jalon Therapeutics Funding Round
Private investors joined a $2.1 million funding round for Jalon Therapeutics. This venture round was announced on 12/16/2022.
Transaction Overview
Company Name
Announced On
12/16/2022
Transaction Type
Venture Equity
Amount
$2,120,000
Round
Undisclosed
Investors
Proceeds Purpose
Jalon Therapeutics, a Paris, France-based biotechnology company specializing in new approaches for inducing cancer cell death.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
27 rue Juliette Dodu
Paris, 75010
FR
Paris, 75010
FR
Phone
Undisclosed
Website
Email Address
Overview
Jalon Therapeutics aims to develop innovative therapies that inactivate yet untargeted vital tumor signaling pathways. Our mission is to develop medicines that will transform the lives of people fighting cancer. For that purpose, we leverage our deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. This mechanism, defined as "non-oncogene addiction" (NOA), offers potential novel, safer and more effective therapeutic strategies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Loison
Chief Operating Officer
Hélène Sicard
Chief Scientific Officer
Jean-Luc Poyet
Co-Founder
Jérôme Tiollier
Browse more venture capital transactions:
Prev: 12/16/2022: Grata venture capital transaction
Next: 12/16/2022: Classet venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs